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ABSTRACT
Pyruvate kinase M2 (PKM2) and pyruvate dehydroge-
nase complex (PDC) regulate production of acetyl-
CoA, which functions as an acetyl donor in di-
verse enzymatic reactions, including histone acety-
lation. However, the mechanism by which the acetyl-
CoA required for histone acetylation is ensured in
a gene context-dependent manner is not clear. Here
we show that PKM2, the E2 subunit of PDC and hi-
stone acetyltransferase p300 constitute a complex
on chromatin with arylhydrocarbon receptor (AhR),
a transcription factor associated with xenobiotic
metabolism. All of these factors are recruited to the
enhancer of AhR-target genes, in an AhR-dependent
manner. PKM2 contributes to enhancement of tran-
scription of cytochrome P450 1A1 (CYP1A1), an AhR-
target gene, acetylation at lysine 9 of histone H3 at
the CYP1A1 enhancer. Site-directed mutagenesis of
PKM2 indicates that this enhancement of histone
acetylation requires the pyruvate kinase activity of
the enzyme. Furthermore, we reveal that PDC activity
is present in nuclei. Based on these findings, we pro-
pose a local acetyl-CoA production system in which
PKM2 and PDC locally supply acetyl-CoA to p300
from abundant PEP for histone acetylation at the
gene enhancer, and our data suggest that PKM2 sen-
sitizes AhR-mediated detoxification in actively prolif-
erating cells such as cancer and fetal cells.
INTRODUCTION
Acetyl-CoA is a central metabolite straddling diverse
metabolic pathways, including glycolysis, the citric acid
cycle, fatty acid oxidation, lipid biosynthesis, ketogenesis
and amino acid metabolism. It also participates in signal
transduction as an acetyl donor for protein acetylation. In
the nucleus, histone acetylation drives chromatin structural
changes to facilitate DNA transcription, replication and re-
pair (reviewed in (1)). While it is well known that acetyl-
CoA production systems exist in mitochondria and the cy-
toplasm, recent reports have revealed that the nucleus also
possesses such systems (2–4). However, the mechanism by
which acetyl-CoA is made available for histone acetylation
in a gene-specific context is still not clear.
Pyruvate kinase and pyruvate dehydrogenase complex
(PDC) regulate a large portion of acetyl-CoA produc-
tion from glucose intermediates. Pyruvate kinase is a
rate-limiting glycolytic enzyme which transfers the phos-
phate group of phosphoenolpyruvate (PEP) to adenosine
diphosphate (ADP) to produce pyruvate and adenosine
triphosphate (ATP). PDC is a mitochondrial protein com-
plex which irreversibly decarboxylates pyruvate to produce
acetyl-CoA, thus connecting glycolysis and the citric acid
cycle. However, recent reports indicate there is significant
crosstalk between these enzymes and nuclear transcription.
Among the four isoforms of pyruvate kinase, the prolifer-
ating cell-specific M2 isoform (PKM2) functions as a co-
activator for several transcription factors involved in regula-
tion of cell proliferation and maintenance of an undifferen-
tiated state (5–8). It has also been reported that PKM2 en-
hances transcriptional activity via its protein kinase activity,
for example through phosphorylation of Tyr705 of STAT3
(5) or Thr11 of histone H3 (9). PDC-E2, one of three PDC
subunits, interacts with STAT5 in the nucleus to enhance
STAT5 transcriptional activity (10). However, whether or
how these enzymes orchestrate transcriptional activation is
still unknown.
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Here, we demonstrate that PKM2, PDC-E2 and histone
acetyltransferase (HAT) p300 constitute a complex in the
nucleus with arylhydrocarbon receptor (AhR), a ligand-
activated transcription factor involved in activating genes
related to xenobiotic metabolism such as cytochrome P450
1A1 (CYP1A1) (11). All these factors (PKM2, PDC-E2 and
p300) are recruited to the CYP1A1 enhancer in an AhR-
dependent manner. Furthermore, we show that PDC ac-
tivity is present in the nucleus and that the pyruvate ki-
nase activity of PKM2 enhances histone H3K9 acetyla-
tion at the enhancer. Based on our findings, we suggest
that PKM2 sensitizes AhR-mediated detoxification in can-
cer cells and fetal cells to ensure proliferation, and propose




Human cervical cancer HeLa S3 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum. Human hepatocarci-
noma HepG2 cells were maintained in DMEM supple-
mented with 10% fetal bovine serum.
Affinity purification of protein complexes
The human cDNAs of AhR (BC070080) and PKM2
(BC000481) were purchased from Open Biosystems (Al-
abama, USA). Transduction of stable FLAG/HA-tagged
AhR or PKM2-expressing HeLa S3 cells and affinity purifi-
cation of AhR or PKM2 complex from a solubilized chro-
matin fraction were according to a previous report (12).
Co-immunoprecipitation
All procedures were performed at 4◦C or on ice. For
co-immunoprecipitation using the chromatin fraction, the
chromatin fraction was incubated with anti-AhR antibody
(N-19, Santa Cruz Biotechnology, CA, USA), anti-PDC-
E2 antibody (ab110332, Abcam, Cambridge, UK), normal
goat IgG (sc-2028, Santa Cruz Biotechnology) or normal
mouse IgG (sc-2025, Santa Cruz Biotechnology) for 2 h.
After protein G-Agarose (Life Technologies, CA, USA)
was added to the sample, the sample was incubated for
further 1 h. Immunoprecipitates were pelleted, washed
with binding buffer (20 mM Tris–HCl pH 8.0, 10 mM
KCl, 0.2 mM, 0.2 mM ethylenediaminetetraacetic acid,
1 mM 2-mercaptoethanol, 0.2 mM phenylmethylsulfonyl
fluoride, 10% glycerol, 0.1% Tween 20) three times and
then eluted in 100 mM glycine–HCl pH 2.5 by incuba-
tion for 5 min. The eluate was neutralized by addition of
1 M Tris–HCl pH 7.3. The eluate was analyzed by west-
ern blotting. For co-immunoprecipitation using whole cell
lysate, HeLa S3 cells were harvested and lysed in Cell Ly-
sis buffer (150 mMNaCl, 0.5% NP-40, 10% glycerol, 2 mM
-mercaptoethanol, 0.2 mMphenylmethylsulfonyl fluoride,
10 mM -glycerophosphate) after experimental treatment.
Lysates were centrifuged at 15 000 rpm for 30 min and
the supernatant was pre-cleared with normal rabbit IgG
(#2729, Cell Signaling Technology, MA, USA) and pro-
tein G-Agarose (Life Technologies, CA, USA). After cen-
trifugation at 3000 rpm for 2 min, the supernatant was in-
cubated with anti-PKM2 antibody (raised in this study as
shown in the ‘Western blotting’ section) or normal rabbit
IgG conjugated with Dynabeads Protein G (Life Technolo-
gies). Immunoprecipitates were pelleted, washed with Cell
Lysis buffer twice, followed by phosphate-buffered saline
and then eluted in 100 mM glycine–HCl pH 2.5 by incuba-
tion for 1 h on ice. The eluate was neutralized by addition of
1 M Tris–HCl pH 8.0. The eluate was analyzed by western
blotting.
Western blotting
Western blotting was carried out according to standard
methods. We used the following antibodies; anti-AhR
(H-211), anti-GAPDH (FL-335) and anti-PDC-E2 (C-
1) antibodies (Santa Cruz Biotechnology), anti-beta-actin
(ab8227) and anti-PDC-E2 (ab110332) antibodies (Ab-
cam), anti-GAPDH antibody (MA1–22670, Thermo, MA,
USA), anti-cytochrome c antibody (556433,BD Pharmin-
gen, NJ, USA), anti-histone H3 (#9715), anti-FLAG
(#2368) and anti-PKM2 (#4053) antibodies (Cell Signal-
ing Technology). Polyclonal anti-PKM2 antibody against
a PKM2-specific peptide (LRRLAPITSDPTEATAVGAV)
was raised in rabbits.
Stable knockdown
Two different 19-nt target sequences were designed:
shPKM2#1-F, 5′- GCTGTGGCTCTAGACACTA-3′;




shAhR#1-R, 5′- TATAACAGACTACTGTCTG -3′;
shAhR#2-F, 5′- CAGCTGAATTAAATAACAT-3′;
shAhR#2-R, 5′- ATGTTATTTAATTCAGCTG-3′. The
60-bp oligonucleotides were synthesized according to the
instruction manual for pSUPER.retro.puro (Oligo Engine,
Seattle, WA, USA). Retroviral production was used to
generate HeLa S3 cells stably expressing shRNAs specific
for PKM2 or AhR, and stable clones were selected with
puromycin.
Real-time RT-PCR
Total RNA was extracted using an RNeasy Mini kit (Qia-
gen, Hilden, Germany) and DNA was on-column digested
using RNase-free DNase Set (Qiagen) during total RNA
extraction. cDNA was synthesized from total RNA using
a QuantiTect Reverse Transcription kit (Qiagen). The syn-
thesized cDNA was amplified using a QuantiFast SYBR
Green polymerase chain reaction (PCR) kit (QIAGEN).
Primer sequences were as follows: CYP1A1-F, 5′-CACCA
TCCCCCACAGCAC-3′; CYP1A1-R, 5′-ACAAAGACA
CAACGCCCCTT-3′; CYP1B1-F, 5′- CTGGCACTGAC
GACGCCAAGAGACT -3′; CYP1B1-R, 5′-TGGTCTG
CTGGATGGACAGCGGGTT-3′; CYP1A2-F, 5′-CCA
ACGTCATTGGTGCCATG-3′; CYP1A2-R, 5′-GTGAT
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GTCCCGGACACTGTTC-3′; β2-microglobulin (β2M)-F,
5′-ACTGAATTCACCCCCACTGA-3′; β2M-R, 5′-CCT
CCATGATGCTGCTTACA-3′. PCRwas performed using
a Thermal Cycler Dice Real Time System TP800 (Takara).
The mRNA levels were normalized against β2M mRNA.
Overexpression of PKM2
The human cDNA of PKM2 (BC000481) was cloned
into pCMV-Tag2A (Stratagene). HepG2 cells were tran-
siently transfected with pCMV-Tag2A/PKM2 using Lipo-
fectamine 2000 (Invitrogen). About 24 h after transfection,
the cells were used for further experiments.
ChIP
After treatment with 100 nM indirubin for 45min, HeLa S3
cells were fixed with 1% formaldehyde at room temperature
for 10 min (for histone) or 20 min (for the other proteins)
and the fixation reaction was stopped with 125 mM glycine.
DNA was immunoprecipitated from sonicated cell lysates.
Antibodies used were as follows: normal rabbit IgG (Cell
Signaling Technology), AhR (N-19) (Santa Cruz Biotech-
nology), p300 (Abcam), acetyl-histone H3 (K9) (Millipore,
MA, USA) and PKM2 (this study). The immunopre-
cipitated DNA was purified and real-time PCR was
performed using the following primers: CYP1A1 enhancer-




AGGCGAAT-3′; CYP1A2 enhancer-F, 5′-GATTCTC
ACGGCAAGAAGGACTCTC-3′; CYP1A2 enhancer-
R, 5′-CCAGCCAGGTATGTGCGTGTTTGTA-3′;
CYP1A1 coding region-F, 5′- CATGTCGGCCA
CGGAGTTTCTTC-3′; CYP1A1 coding region-R,
5′- ACAGTGCCAGGTGCGGGTTCTTTC-3′. As a
negative control of genome region, SimpleChIP Human 
Satellite Repeat Primers (Cell signaling) was used. Quan-
titative analysis was confirmed by comparing the dilution
series of the input fraction.
Rescue experiment
The human cDNA of PKM2 (BC000481) was cloned
into p3xFLAG CMV14 (Sigma-Aldrich). Site-directed
mutagenesis for shPKM2-resistant PKM2 and PKM2
K367M mutant was performed using a PrimeSTAR Mu-
tagenesis Basal Kit (Takara, Shiga, Japan). HeLa S3
cells expressing shPKM2 #1 were transiently transfected
with p3xFLAG CMV14, p3xFLAG CMV14/shPKM2
#1-resistant PKM2 or p3xFLAG CMV14/shPKM2 #1-
resistant PKM2 K367M using Lipofectamine 2000. About
24 h after transfection, the cells were subjected to further
experiments.
Pyruvate kinase assay
Pyruvate kinase activity was measured according to Chris-
tifk et al. (13). For the pyruvate kinase assay of whole-cell
lysates, 1 g of total protein was used in a volume of 100
l. After the mixture was incubated at 37◦C for 30 min, the
reaction was stopped by adding 100 l of 100 mM glycine–
HCl pH 2.5. The mixture was then filtered with an Ami-
conUltra 3K device (nominal molecular weight limit, 3000)
(Merk, Darmstadt, Germany) by centrifugation for 15 min
at 15 000 rpm, 4◦C. The NAD+ in the filtrate was mea-
sured by HPLC (Waters, MA, USA). The sample was in-
jected and separated on a Shin-pack XR-ODS column (3.0
× 75 mm) (Shimadzu, Kyoto, Japan). Elution was carried
out as follows (solvent A, 10 mM ammonium acetate; sol-
vent B, methanol): 0–3 min, isocratic with 0% B; 3–15 min,
linear gradient to 4% B; 15–20 min, linear gradient to 80%
B; 20–25min, isocratic with 80%B; 25–25.1 min, linear gra-
dient to 0% B; 25.1–36 min, isocratic with 0% B; flow rate,
0.2 ml/min. For detection of NAD+, absorbance at 260 nm
was monitored. The amount of NAD+ was quantified by
calculating the peak area ratio of NAD+. For the pyruvate
kinase assay of the purified nuclear fraction sample, 3 g of
total protein was used. The incubation time was 10 min.
Subcellular fractionation
Cells were suspended with the six volumes of hypotonic
buffer (10 mM Tris–HCl pH 7.3, 10 mM KCl, 1.5 mM
MgCl2, 0.2 mM phenylmethylsulfonyl fluoride, 10 mM -
glycerophosphate and 10mM -mercaptoethanol) and cen-
trifuged at 1300 x g for 5 min. The cell pellet was resus-
pended in an equal volume of hypotonic buffer. After in-
cubation on ice for 10 min, the cells were homogenized by
forcing them through a 25-gauge needle so that at least
80% of cells were broken and nuclei were exposed. The nu-
clei were pelleted by centrifugation at 600 x g for 10 min.
The supernatant was centrifuged at 8000 x g for 10 min.
The pellet was washed with 0.34 M sucrose in Tris, KCl,
MgCl2 (TKM) buffer (50 mM Tris–HCl pH 7.3, 25 mM
KCl, 5 mM MgCl2, 0.2 mM phenylmethylsulfonyl fluoride
and 10 mM -glycerophosphate), suspended in 0.34 M su-
crose in TKM buffer and retained as a crude mitochondrial
fraction. The nuclear pellet was suspended in 0.25 M su-
crose in TKM buffer, layered over 1.6 M sucrose in TKM
buffer and centrifuged at 13 000 rpm for 30min. The nuclear
pellet was washed with 0.25 M sucrose in TKM buffer and
resuspended in 0.34M sucrose in TKMbuffer (nuclear frac-
tion). All samples were frozen in liquid nitrogen and stored
at −80◦C until use. Repeated freezing and thawing of sam-
ples was avoided.
PDC activity assay
A previous report was used as a reference (14). Ten micro-
gram of total protein was used in the PDC assay in a vol-
ume of 100 l. After incubating the mixture at 37◦C for 10
min, the reaction was stopped by adding 100 l of 100 mM
glycine–HCl pH 2.5. The mixture was then filtered with an
Amicon Ultra 3K device by centrifugation for 15 min at 15
000 rpm, 4◦C. The product, acetyl-CoA, was measured by
LC/MS/MS. LC/MS/MS analysis was carried out using a
Quattro Ultima Pt triple stage quadrupole mass spectrom-
eter (Waters) equipped with a Waters LC system. The LC
separation was according to a previous report (15). Multi-
reaction monitoring was performed in negative ion mode
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using nitrogen as the nebulizing gas. Experimental condi-
tions were as follows: ion source temperature, 130◦C; desol-
vation temperature, 380◦C; capillary voltage, 2.4 kV; cone
voltage, 35 V; collision energy, 15 eV; desolvation gas flow
rate, 700 L/h; cone gas flow rate, 35 L/h; collision gas, ar-
gon. The MRM transition for acetyl-CoA was m/z 808.0
→ 407.7. The amount of acetyl-CoA was quantified by cal-
culating the peak area ratio of acetyl-CoA. The kinetics pa-
rameters (Km and Vmax) were fitted to a Hanes–Woolf plot.
RESULTS
PKM2, PDC-E2 and p300 constitute a complex with AhR on
chromatin
To identify components of the ligand-stimulated AhR com-
plex, HeLa S3 cells stably expressing FLAG-HA-tagged
AhR (eAhR) were treated with 100 nM indirubin, a potent
endogenous AhR ligand (16), for 3 h. The chromatin frac-
tion was prepared as indicated in the ‘Experimental pro-
cedures’ section and eAhR complex was purified by affin-
ity chromatography on anti-FLAG antibody-conjugated
agarose. We detected PKM2, PDC-E2 and p300 in the
eAhR complex (Figure 1A). These proteins were not de-
tected in the mock control, indicating specific interactions
between AhR and these proteins. To confirm the interac-
tions, FLAG-HA-tagged PKM2 (ePKM2) complexwas pu-
rified from the chromatin fraction of HeLa S3 cells sta-
bly expressing ePKM2 under the same conditions. Con-
sistent with the previous co-immunoprecipitation experi-
ment, we detected AhR, PDC-E2 and p300 in the ePKM2
complex but not in the mock control (Figure 1B). Endoge-
nous PKM2 was also detected in the PKM2 complex since
PKM2 can exist as a dimer or tetramer (reviewed in (17)).
We also detected PKM2 and PDC-E2 in immuniprecipitate
using anti-AhR antibody from the chromatin fraction of
HeLa S3 cells (Figure 1C) and AhR and PKM2 in immuni-
precipitate using anti-PDC-E2 antibody (Figure 1D). These
findings indicate that PKM2, PDC-E2, p300 and AhR con-
stitute a complex on chromatin.
PKM2 enhances AhR-mediated transcriptional activation
We next focused on the AhR–PKM2 interaction. Co-
immunoprecipitation using anti-FLAG antibody or anti-
PKM2 antibody confirmed the interaction between AhR
and PKM2, and the interaction was enhanced by indirubin
treatment (Figure 1E and F).
We investigated the significance of the AhR-PKM2
interaction in AhR-mediated transcriptional activation.
Knockdown experiment indicates that neither AhR nor
PKM2 affect each other in protein expression level (Fig-
ure 2A). As reported, AhR knockdown significantly sup-
pressed indirubin-induced CYP1A1 mRNA expression
(Figure 2B). PKM2 knockdown resulted in a significant re-
duction in CYP1A1mRNA level in cells exposed to indiru-
bin (Figure 2C). Conversely, PKM2 overexpression signifi-
cantly increased CYP1A1 mRNA expression in indirubin-
treated cells (Figure 2D and E). We tested the other AhR-
target genes CYP1B1 and CYP1A2. PKM2 knockdown
suppressed CYP1B1 mRNA induction by indirubin (Fig-
ure 2F). PKM2 knockdown also showed tendency to sup-
pressCYP1A2mRNA induction by indirubin although the
effect was not statistically significant (Figure 2G).
In cancer cells, lactate dehydrogenase, which converts
pyruvate to lactate, is overexpressed and the pyruvate con-
centration is low compared with normal cells (18). The
fact prompted us to elucidate a significance of PKM2
in AhR-mediated transcriptional activation in pyruvate-
depleted condition. Figure 2H shows that the suppres-
sion of indirubin-induced CYP1A1 mRNA expression by
PKM2 knockdown was more drastic in pyruvate-depleted
condition than that in normal condition (Figure 2C). These
data are consistent with the idea that PKM2 enhances AhR
transactivation.
PKM2 is recruited to gene enhancers of the AhR-target genes
in an AhR-dependent manner
Next, to determine whether PKM2 directly regulates AhR-
mediated transcription, a ChIP assay was performed. Af-
ter HeLa S3 cells were exposed to 100 nM indirubin for 45
min, the presence of AhR was significantly increased at the
enhancers of CYP1A1, CYP1B1 and CYP1A2 (Figure 3A
and B). PKM2 depletion did not affect AhR occupancy at
the CYP1A1 enhancer (Figure 3A), indicating that recruit-
ment of AhR to the gene enhancers was independent of
PKM2. Interestingly, PKM2 was significantly enriched at
the CYP1A1 enhancer by indirubin treatment (Figure 3C).
PKM2 was also enriched at the coding region of CYP1A1
by indirubin treatment but the increase was less than PKM2
at the CYP1A1 promoter (Figure 3D). This data suggests
that PKM2 preferably binds to the enhancer rather than
the gene body. PKM2 presence was significantly decreased
in AhR-depleted cells (Figure 3C), indicating that PKM2
is recruited to the enhancers in an AhR-dependent man-
ner.We also tested the enhancers ofCYP1B1 andCYP1A2.
PKM2 was significantly enriched at the CYP1B1 enhancer
by indirubin treatment. In case of the CYP1A2 enhancer,
the significant enrichment of PKM2was not observed (Fig-
ure 3E). These data suggest that PKM2 directly controls
transactivation of at least a range of AhR-target genes.
The pyruvate kinase activity of PKM2 enhances acetylation
of K9 in histone H3 at the CYP1A1 gene enhancer
To elucidate a role for PKM2 at the gene enhancer, we next
examined whether PKM2 affects histone acetylation, espe-
cially acetylation at lysine 9 of histone H3 (H3K9), which
is known to be associated with activation of transcription.
PKM2 knockdown did not apparently affect overall H3K9
acetylation levels or total amount of proteins identified
from AhR/PKM2 complex, compared with normal HeLa
S3 cells (Figure 4A). However, ChIP assays revealed that
PKM2 knockdown significantly decreased H3K9 acetyla-
tion levels at the CYP1A1 enhancer in cells treated with in-
dirubin (Figure 4B). Since p300 is a known transcriptional
co-activator for AhR transactivation (19,20), we next in-
vestigated whether the observed reduction in histone acety-
lation could be attributed to reduced p300 recruitment at
the CYP1A1 enhancer. PKM2 knockdown in cells did not
affect recruitment of p300 to the CYP1A1 enhancer (Fig-
ure 4C and D).
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Figure 1. AhR, PKM2, PDC-E2 and p300 constitute a complex in the chromatin fraction. (A) eAhR complex was purified from a solubilized chromatin
fraction of stably transduced HeLa S3 cells after treatment with 100 nM indirubin for 3 h, and analyzed by western blotting. A mock purification was
performed using non-transduced HeLa S3 cells. (B) ePKM2 complex was purified from a solubilized chromatin fraction of stably transduced HeLa S3
cells after treatment with 100 nM indirubin for 3 h and analyzed by western blotting. A mock purification was performed using non-transduced HeLa
S3 cells. (C) Endogenous AhR was immunoprecipitated by anti-AhR antibody from the chromatin fraction of HeLa S3 cells. (D) Endogenous PDC-E2
was immunoprecipitated by anti-PDC-E2 antibody from the chromatin fraction of HeLa S3 cells. (E) eAhR complex was immunoaffinity-purified by anti-
FLAG antibody-conjugated agarose from whole-cell lysates of eAhR-expressing HeLa S3 cells not treated (−) or treated (+) with 100 nM indirubin for 3
h. F. PKM2 complex was immunoprecipitated using anti-PKM2 antibody from whole-cell lysates of HeLa S3 cells not treated (−) or treated (+) with 100
nM indirubin for 1 h.
To determine whether histone acetylation at theCYP1A1
enhancer requires the enzymatic activity of PKM2, we
performed rescue experiments. FLAG- tagged, shRNA-
resistant wild-type PKM2 or a PKM2 K367M mutant,
which lacks pyruvate kinase activity (21), was expressed
in PKM2-knockdown HeLa S3 cells (Figure 5A and B),
the cells were treated with 100 nM indirubin for 45 min,
and then ChIP assays were performed. As shown in Fig-
ure 5C, overexpression of wild-type PKM2 increasedH3K9
acetylation at the CYP1A1 enhancer, whereas overexpres-
sion of the PKM2K367Mmutant failed to do so, indicating
that efficient histone acetylation at the CYP1A1 enhancer
requires the pyruvate kinase activity of PKM2. Next, we
tested whether pyruvate kinase activity affects the tran-
scriptional activity of AhR. Note that PEP is a substrate
of PKM2 and a source of pyruvate, and that PKM2 is
allosterically activated by a glycolytic metabolite, fructose
1,6-bisphosphate (FBP), which is not the case for PKM1
(22). Therefore, we examined the effects of these two sub-
stances (PEP and FBP) on AhR-mediated transactivation.
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Figure 2. PKM2 promotes AhR transactivation. (A) HeLa S3 cells were transduced with two retroviruses encoding different shRNAs targeting PKM2
(shPKM2) or two retroviruses encoding different shRNAs targeting AhR (shAhR). Non-transducedHeLa S3 cells were used as controls.Whole-cell lysates
were subjected to western blotting. (B) After AhR in HeLa S3 cells was knocked down with shRNA targeting different sites of the AhR gene (shAhR #1),
the cells were exposed to DMSO or 10 nM indirubin for 2 h. CYP1A1 mRNA levels were measured by real-time RT-PCR (mean ± SD, n = 3). ##P <
0.01, ###P< 0.001 versus DMSO, ***P< 0.001 (Student’s t-test). (C) After PKM2 in HeLa S3 cells was knocked down with shRNAs targeting different
sites of the PKM2 gene (shPKM2 #1, #2), the cells were exposed to DMSO or 10 nM indirubin for 2 h.CYP1A1mRNA levels were measured by real-time
RT-PCR (mean ± SD, n = 3). ##P < 0.01, ###P < 0.001 versus DMSO, **P < 0.01 (Student’s t-test). (D) HeLa S3 cells were transfected with pCMV-
Tag2A (vector control) or pCMV-Tag2A/PKM2. After 24 h, whole-cell lysates were subjected to western blotting. (E) After HeLa S3 cells transfected with
pCMV-Tag2A (vector control) or pCMV-Tag2A/PKM2 were exposed to DMSO or 100 nM indirubin for 6 h, CYP1A1 mRNA levels were measured by
real-time RT-PCR (mean ± SD, n = 5). ###P < 0.001 versus DMSO, ***P < 0.001 (Student’s t-test). (F and G) HeLa S3 cells non-transfected (control)
or transfected with shPKM2 #1 were exposed to DMSO or 10 nM indirubin for 2 h. mRNA levels of CYP1B1 (F) and CYP1A2 (G) were measured by
real-time RT-PCR (mean ± SD, n = 3). ##P < 0.01 versus DMSO, **P < 0.01 (Student’s t-test). (H) HeLa S3 cells were conditioned in medium without
pyruvate for 24 h and treated with 10 nM indirubin for 2 h. Then, CYP1A1mRNA levels were measured by real-time RT-PCR (mean ± SD, n = 3). ##P
< 0.01 vs. DMSO, ***P < 0.001 (Student’s t-test).
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Figure 3. PKM2 is recruited to gene enhancers of the AhR-target genes in an AhR-dependent manner. (A and B) HeLa S3 cells non-transfected (control)
or transfected with shPKM2 #1 were exposed to DMSO or 100 nM indirubin for 45 min. ChIP assays were performed with IgG or anti-AhR antibody
(mean ± SD, n = 3). -satellite repeat was used as a negative control of genome region. #P < 0.05, ###P < 0.001 versus DMSO, *P < 0.05, **P < 0.01
(Student’s t-test). (C, D and E) HeLa S3 cells non-transfected (control) or transfected with shAhR #1 were exposed to DMSO or 100 nM indirubin for
45 min. ChIP assays were performed with IgG or anti-PKM2 antibody (mean ± SD, n = 3). -satellite repeat was used as a negative control of genome
region. ##P < 0.01, ###P < 0.001 versus DMSO, **P < 0.01 (Student’s t-test).
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Figure 4. PKM2 promotes histone acetylation at the CYP1A1 enhancer. (A) Whole-cell lysates of HeLa S3 cells non-transfected (control) or transfected
with shPKM2 #1 were subjected to western blotting. (B) HeLa S3 cells non-transfected (control) or transfected with shPKM2#1 were exposed to DMSO
or 100 nM indirubin for 45 min. ChIP assays were performed with IgG or anti-histone H3K9ac antibody (mean ± SD, n = 3). ##P < 0.01 versus DMSO,
**P < 0.01 (Student’s t-test). (C and D) HeLa S3 cells non-transfected (control) or transfected with shPKM2 #1 were exposed to DMSO or 100 nM
indirubin for 45 min. ChIP assays were performed with IgG or anti-p300 (mean ± SD, n = 3). -satellite repeat was used as a negative control of genome
region. ###P < 0.001 versus DMSO (Student’s t-test).
Since PEP and FBP are mainly derived from glucose via
glycolysis, in order to potentiate their effects, HeLa S3 cells
were conditioned in medium without glucose for 24 h to de-
plete intracellular PEP and FBP. After glucose depletion,
the cells were co-treated with 10 nM indirubin together with
5 mM PEP and/or 5 mM FBP. The CYP1A1 mRNA level
was significantly decreased by glucose depletion, and was
moderately rescued by PEP or FBP treatment. On the other
hand, co-treatment with PEP and FBP resulted in a syn-
ergistic increase in the CYP1A1 mRNA level (Figure 5D).
This result is consistent with an idea that pyruvate kinase
activity promotes the transcriptional activity of AhR.
The nucleus has PDC activity and PDC-E2 is recruited to the
CYP1A1 gene enhancer in an AhR ligand-dependent manner
The next question we addressed was why pyruvate kinase
activity is necessary for histone acetylation at the CYP1A1
enhancer. It is well known that pyruvate is used by PDC
to generate acetyl-CoA in mitochondria. In this study, we
detected PDC-E2 in complexes with AhR and PKM2 im-
munoprecipitated from nuclear chromatin (Figure 1). Con-
sistent with those findings, we detected PDC-E2 by western
blotting in a carefully purified nuclear fraction (Figure 6A).
Histone H3 present in the mitochondrial fraction is con-
sistent with previous reports (23,24). Furthermore, the nu-
clear fraction was able to produce acetyl-CoA from pyru-
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Figure 5. Pyruvate kinase activity of PKM2 promotes histone acetylation at the CYP1A1 enhancer. (A) HeLa S3 cells expressing shPKM2 #1 were
transfected with empty vector, vector encoding shPKM2 #1-resistant PKM2 wild-type (WT)-3xFLAG (wild-type PKM2) or PKM2 K367M-3xFLAG
(mutant type PKM2). Whole-cell lysates were subjected to western blotting. (B) HeLa S3 cells expressing shPKM2 #1 were transfected with empty vector,
vector encoding shPKM2#1-resistant PKM2WT-3xFLAGor PKM2K367M-3xFLAG. After cell lysis, pyruvate kinase activity was assayed (mean± SD,
n= 3). ***P< 0.001 (Student’s t-test). (C) HeLa S3 cells expressing shPKM2#1were transfected with empty vector, vector encoding shPKM2#1-resistant
PKM2WT-3xFLAGor shPKM2#1-resistant PKM2K367M-3xFLAG and exposed to 100 nM indiruin for 45 min. ChIP assays were performed with IgG
or anti-histone H3K9ac antibody (mean ± SD, n = 3). n.s., not significant; *P < 0.05, **P < 0.01 (Student’s t-test). (D) HeLa S3 cells were conditioned in
medium with 4.5 g/l glucose or without glucose for 24 h and treated with 100 nM indirubin or co-treated with 100 nM indirubin and 5 mM PEP and/or 5
mM FBP for 2 h. Then, CYP1A1mRNA levels were measured by real-time RT-PCR (mean ± SD, n= 3). *P< 0.05, **P< 0.01, ***P< 0.001 (Student’s
t-test).
vate (Figure 6B). The Km for pyruvate was similar between
the mitochondrial and nuclear fractions, but theVmax of the
nuclear fraction was about 16% of that of the mitochon-
drial fraction, which is fairly consistent with the difference
in PDC-E2 protein levels between the two fractions. These
results indicate that PDC in the nucleus is equally able to
utilize pyruvate to make acetyl-CoA as PDC in the mito-
chondria, consistent with a recent report (4). This prompted
us to ask whether PDC-E2 is recruited to the CYP1A1 en-
hancer. After HeLa S3 cells were treated with 100 nM in-
dirubin for 45 min, binding of PDC-E2 to the CYP1A1 en-
hancer was determined by ChIP assay. Enrichment of PDC-
E2 was significantly increased by indirubin treatment (Fig-
ure 6C), indicating that PDC-E2 is recruited to theCYP1A1
enhancer following ligand activation of AhR.
DISCUSSION
We showed here that p300, PDC-E2 and PKM2 are re-
cruited to the CYP1A1 gene enhancer together with AhR,
and these factors constitute a complex on chromatin. We
also found that PDC activity, which produces acetyl-CoA
from pyruvate and CoA, and pyruvate kinase activity,
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Figure 6. The nucleus has PDC activity and PDC-E2 is recruited to the CYP1A1 enhancer in an AhR-ligand-dependent manner. (A) HeLa S3 cells were
fractionated into cytoplasmic, mitochondrial and nuclear fractions. The nuclear fraction was further purified by sucrose density-gradient centrifugation
as described in the Experimental procedures section. Lysates of each fraction were subjected to western blotting. (B) Kinetics parameters of acetyl-CoA
production from pyruvate in each fraction. Each fraction was subjected to a PDC assay as described in the ‘Materials and Methods’ section, and the
apparent Km for pyruvate and apparent Vmax were determined (mean ± SE, n = 3). (C) HeLa S3 cells were exposed to 100 nM indirubin for 45 min. ChIP
assays were performed with IgG or anti-PDC-E2 antibody (mean ± SD, n = 3). *P < 0.05, ***P < 0.001 (Student’s t-test).
which produces pyruvate and ATP from PEP and ADP, are
present in the nucleus (data not shown). On the other hand,
the fact that PKM2 knockdown did not affect bulk histone
acetylation (Figure 4A) suggests that PKM2 might control
local histone acetylation rather than bulk acetylation. To-
gether, we suggest that these enzymes are assembled to con-
struct a local acetyl-CoA supply system for histone acetyla-
tion at theCYP1A1 gene enhancer (Figure 7). In thismodel,
CoA could be immediately recycled to acetyl-CoA by PDC
using pyruvate. Thus, by this mechanism, the acetyl-CoA
concentration in proximity to p300 at the gene enhancer
could be stably maintained at a high level when and where
it is required.
Among endogenous AhR ligands reported (16,25,26),
the potent AhR ligand indirubin also functions as an anti-
cancer drug to inhibit cyclin-dependent kinases (27). Thus,
accumulation of the highly-insoluble compound is harm-
ful especially to proliferating cells such as cancer and fetal
cells. On the other hand, CYP1A1 induced by AhR activa-
tion can easily metabolize indirubin (28), emphasizing the
Figure 7. Hypothetical model based on this study. Nuclear PKM2 and
PDC coordinately serve as a ‘supplier’ of acetyl-CoA in the CYP1A1 en-
hancer region. The CoA byproduct of histone acetylation is immediately
recycled to acetyl-CoA by PDC.
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importance of the AhR-mediated detoxification system in
proliferating cells. Previous reports show that PKM2 in tu-
mor and fetal cells is expressed at much higher levels than
in the adult (29–32), whereas AhR is expressed in tumor, fe-
tal and adult tissues. Our results indicate that PKM2 would
confer an advantage to proliferating cells by allowing them
to effectively eliminate harmful endogenous metabolites or
exogenous chemicals and thereby support cell proliferation.
In contrast to its role in detoxification, AhR also medi-
ates the toxicity of dioxins, which are potent exogenous and
highly stable AhR ligands (33–35). Fetuses, especially, are
highly-sensitive to dioxins by still unknown mechanisms.
Exposure of dioxins to pregnant mice can induce fetal mal-
formations such as hydronephrosis and cleft palate with-
out severe toxicity to the dams, and these teratogenic ef-
fects are dependent on AhR expression (36,37). Enhance-
ment of AhR activation by PKM2 is thought to occur pref-
erentially in the fetus, resulting in fetal hypersensitivity to
dioxins. On the other hand, it should be noted that the Ah-
responsiveness of different AhR ligands is structure-, cell
context- and response-dependent (38).
Our model is also interesting in terms of the significance
of PKM2 in tumorigenesis. Previous studies have shown
that PKM2 is a major component of the Warburg effect
and regulates switching of glucose utilization between en-
ergy production and synthesis of cellular building blocks in
proliferating cells (13,17). In cancer cells, lactate dehydro-
genase, which converts pyruvate to lactate, is overexpressed
and the pyruvate concentration is low compared with nor-
mal cells (18). Even in this situation, as envisioned by our
model, cancer cells could still supply acetyl-CoA to sites of
transcription by using nuclear PKM2 to generate pyruvate
from its abundant substrate, PEP.
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